LEGISLATIVE BUDGET BOARD Austin, Texas FISCAL NOTE, 88TH LEGISLATIVE REGULAR SESSION March 16, 2023 TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: SB241 by Perry (Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability), Committee Report 1st House, Substituted No significant fiscal implication to the State is anticipated. It is assumed that any costs associated with the bill could be absorbed using existing resources. Local Government ImpactNo fiscal implication to units of local government is anticipated. Source Agencies: b > td > 529 Health and Human Services Commission, 537 State Health Services, Department of LBB Staff: b > td > JMc, NPe, ER, CST
LEGISLATIVE BUDGET BOARD
Austin, Texas
FISCAL NOTE, 88TH LEGISLATIVE REGULAR SESSION
March 16, 2023
TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: SB241 by Perry (Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability), Committee Report 1st House, Substituted
TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services
FROM: Jerry McGinty, Director, Legislative Budget Board
IN RE: SB241 by Perry (Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability), Committee Report 1st House, Substituted
Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services
Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services
Jerry McGinty, Director, Legislative Budget Board
Jerry McGinty, Director, Legislative Budget Board
SB241 by Perry (Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability), Committee Report 1st House, Substituted
SB241 by Perry (Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability), Committee Report 1st House, Substituted
No significant fiscal implication to the State is anticipated.
No significant fiscal implication to the State is anticipated.
It is assumed that any costs associated with the bill could be absorbed using existing resources.
Local Government Impact
No fiscal implication to units of local government is anticipated.
Source Agencies: b > td > 529 Health and Human Services Commission, 537 State Health Services, Department of
529 Health and Human Services Commission, 537 State Health Services, Department of
LBB Staff: b > td > JMc, NPe, ER, CST
JMc, NPe, ER, CST